France Diabetes Therapeutics Market Analysis

France Diabetes Therapeutics Market Executive Analysis

France's diabetes therapeutics market size is at around $3.95 Bn in 2022 and is projected to reach $7.71 Bn in 2030, exhibiting a CAGR of 8.7% during the forecast period. The French budget for 2023 was unveiled on Monday and sees spending rise by $8 Bn from 2021 to 2023. However, without a majority in the assembly, it may be difficult to approve the bill and there is a chance that a no-confidence vote could topple the government. Investments in young children and the development of a more inclusive society for those with disabilities will be made with money set aside for the health industry. In terms of disabilities, France performs poorly and has yet to put into effect the directive to increase the accessibility of products and services.  The French government has increased health spending by $5 Bn to 2.7 % of GDP or the cost of national health insurance. The funds will be used to modernize the healthcare system, which will enhance local healthcare delivery and the standard of care given by public hospitals.

The prevalence of diabetes in the French community is estimated to be 6%, including those receiving oral antidiabetic drugs and/or insulin (4.4%), those receiving diet-only treatment (0.6%), and those who are undiagnosed (1%). 92% of instances of diabetes are type 2 (by far the most common type). Imeglimin is the first member of a new family of oral antidiabetic medications known as "limits" that contain tetrahydro triazine. An in vivo phenotypic screen (based on antihyperglycemic activity in rodents) and extra chemical modification of a lead molecule led to its identification. Imeglimin's mode of action is different from that of other significant classes of therapeutic agents. It has two effects: it improves insulin activity while also reversing pancreatic beta-cell dysfunction. Imeglimin's mode of action is usually in line with how T2D pathophysiology is currently understood. The disease is fueled by a combination of genetic predisposition and important environmental variables, particularly overnutrition and decreased energy expenditure.6 As a result, pancreatic islet-cell dysfunction and flaws in insulin action combine to cause glucose intolerance, which eventually leads to the development of overt diabetes.

Today, a variety of therapeutic agent classes are accessible for the treatment of T2D. However, these drugs frequently only provide a minimal amount of benefit, and they may also pose a danger to patient safety or be poorly tolerated by some patients. As a result, there is a constant need for novel treatments that concentrate on fundamental elements of pathophysiology and have the potential to address ongoing medical needs. The distinct mode of action of meglumine is in line with its recognized clinical profile and may support its possible inclusion in the upcoming therapeutic paradigm.

Market Dynamics

Market Growth Drivers

In France, diabetes is becoming more common among people of all ages, which can be ascribed to an increase in the number of obese people, unhealthy diets, and sedentary lifestyles. As a result, factors such as the rising incidence of diabetes and obesity, increased knowledge of diabetic care, rising healthcare costs, and technological advancements are some of those that are further fuelling the France diabetes therapeutics market expansion.

Market Restraints

The approval procedure for new diabetes therapeutics may be slowed down by the complex and stringent regulatory environment in France. Diabetes medications may have adverse effects or safety issues, which could restrict their use and create a negative perception among patients and healthcare workers. Due to France's comparatively high cost of diabetes care, some patients may not have access to diabetes therapeutics thus limiting the growth of the France diabetes therapeutics market.

Competitive Landscape

Key Players

• AdipoPharma (FRA)- AdipoPharma is using adipocyte power to address type 2 diabetes, insulin resistance, and related conditions.
• Ariana Pharmaceuticals (FRA)
• Pharmaleads (FRA)
• Elaiapharm (FRA)
• AdhexPharma (FRA)
• Novo Nordisk
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Eli Lilly
• Merck
• Sanofi
• Salix Pharmaceuticals

Notable Deals

January 2023- A French biotech company called AdipoPharma has revealed that it has obtained Series A financing for its type 2 diabetes drug development. It anticipates starting clinical trials later this year with a drug that would mark the first significant advancement in the therapy of type 2 diabetes in over ten years. AdipoPharma treats Type 2 diabetes with a cutting-edge strategy. PATAS, a medication by AdipoPharma, treats insulin resistance, the underlying cause of Type 2 diabetes, in contrast to most existing diabetes medications that only address the disease's symptoms. PATAS was created while researching adipocytes, which are adipose cells. PATAS improves adipocytes' ability to withstand insulin, which improves lipid biosynthesis.

March 2022- Glooko selects Diabnext to introduce a digital tool for managing diabetes in France. The platform formerly known as Diabnext has been renamed Glooko XT as a result of the purchase. Diabetes patients in France will have access to both it and Glooko's current platform, which was created initially in collaboration with Novo Nordisk. Glooko will also continue to provide support for those who already use the Diabnext app.

Healthcare Policies and Regulatory Landscape

The Ministry of Health is in charge of the Agence nationale de sécurité du médicament et des produits de santé (ANSM), a governmental organization. On behalf of the French government, it promotes access to therapeutic innovation and guarantees the security of medical products. It collaborates with medical professionals to provide care for patients after consulting with the individuals who represent them and are involved in each Agency body. The ANSM is actively engaged in both European and global activity. Its operations are closely aligned with those of the European Union as a whole, and its efforts are coordinated with those of the European Medicines Agency, the European Commission, and other state agencies. Additionally, it works with global health organizations. After being approved and marketed, drugs and health products must also be monitored for safety and efficacy. If required, the ANSM must take regulatory action to safeguard the public's health. It collaborates closely with other EU regulatory bodies, such as the European Medicines Agency (EMA) and the European Commission, to guarantee the efficacy and safety of medicines and healthcare goods across the EU.